Kurt Huber

Showing 1-15 of 15 articles

Coronary interventions

Safety and Efficacy of Ticagrelor Monotherapy According to Drug-Eluting Stent Type: The TWILIGHT-STENT Study

Baber U, Sharma S, Giustino G, Sartori S, Nicolas J, Goel R, Mehta S, Cohen D, Angiolillo D, Zhang Z, Camaj A, Cao D, Briguori C, Dudek D, Escaned J, Huber K, Collier T, Kornowski R, Kunadian V, Moliterno DJ, Ohman EM, Weisz G, Gil R, Krucoff M, Kaul U, Oldroyd K, Sardella G, Shlofmitz R, Witzenbichler B, Kastrati A, Han Y, Steg P, Pocock S, Gibson CM, Mehran R

August 26, 2021 | 10.4244/EIJ-D-21-00721

Culprit lesion location and outcomes in patients with multivessel disease and infarct-related cardiogenic shock: a core laboratory analysis of the CULPRIT-SHOCK trial

Hauguel-Moreau M, Barthélémy O, Farhan S, Huber K, Rouanet S, Zeitouni M, Guedeney P, Hage G, Vicaut E, Zeymer U, Desch S, Thiele H, Montalescot G

August 6, 2021 | 10.4244/EIJ-D-20-00561

Joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices

Chieffo A, Dudek D, Hassager C, Combes A, Gramegna M, Halvorsen S, Huber K, Kunadian V, Maly J, Møller J, Pappalardo F, Tarantini G, Tavazzi G, Thiele H, Vandenbriele C, Van Mieghem N, Vranckx P, Werner N, Price S

July 20, 2021 | 10.4244/EIJY21M05_01

Coronary interventions

Culprit lesion location and outcomes in patients with multi-vessel disease and infarct-related cardiogenic shock. A core laboratory analysis of the CULPRIT-SHOCK trial

Hauguel-Moreau M, Barthelemy O, Farhan S, Huber K, Rouanet S, Zeitouni M, Guedeney P, Hage G, Vicaut E, Zeymer U, Desch S, Thiele H, Montalescot G

September 8, 2020 | 10.4244/EIJ-D-20-00561

EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic

Chieffo A, Stefanini G, Price S, Barbato E, Tarantini G, Karam N, Moreno R, Buchanan G, Gilard M, Halvorsen S, Huber K, James S, Neumann F, Möllmann H, Roffi M, Tavazzi G, Mauri Ferre J, Windecker S, Dudek D, Baumbach A

June 25, 2020 | 10.4244/EIJY20M05_01

Coronary interventions

Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trial

Fabris E, van't Hof A, Hamm C, Lapostolle F, Flensted Lassen J, Goodman S, ten Berg J, Bolognese L, Cequier A, Chettibi M, Hammett C, Huber K, Janzon M, Merkely B, Storey R, Zeymer U, Cantor W, Rousseau H, Vicaut E, Montalescot G

May 15, 2017 | 10.4244/EIJ-D-16-00965

Coronary interventions

Bivalirudin in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: uncertainties almost clarified

Huber K, Verheugt F

March 20, 2017 | 10.4244/EIJV12I16A315

Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement

Capodanno D, Lip G, Windecker S, Huber K, Kirchhof P, Boriani G, Lane D, Gilard M, Collet J, Valgimigli M, Byrne R

January 22, 2015 | 10.4244/EIJV10I9A174

Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force

Gorenek B, Blomström-Lundqvist C, Terradellas J, Camm A, Hindricks G, Huber K, Kirchhof P, Kuck K, Kudaiberdieva G, Lin T, Raviele A, Santini M, Tilz R, Valgimigli M, Vos M, Vrints C, Zeymer U, Kristiansen S

January 22, 2015

An increase of VEGF plasma levels is associated with restenosis of drug-eluting stents

Katsaros K, Kastl S, Krychtiuk K, Hutter R, Zorn G, Maurer G, Huber K, Wojta J, Christ G, Speidl W

June 20, 2014 | 10.4244/EIJV10I2A36

Consensus document on the radial approach in percutaneous cardiovascular interventions: position paper by the European Association of Percutaneous Cardiovascular Interventions and Working Groups on Acute Cardiac Care** and Thrombosis of the European Society of Cardiology

Hamon M, Pristipino C, Di Mario C, Nolan J, Ludwig J, Tubaro M, Sabaté M, Mauri Ferre J, Huber K, Niemela K, Haude M, Wijns W, Dudek D, Fajadet J, Kiemeneij F

March 22, 2013 | 10.4244/EIJV8I11A192

De Luca G, Gibson CM, Huber K, Dudek D, Cutlip D, Zeymer U, Gyöngyösi M, Bellandi F, Noc M, Arntz H-R, Maioli M, Secco G, Zorman S, Gabriel H, Emre A, Rakowski T, van't Hof A

August 24, 2012 | 10.4244/EIJV8I4A74

Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions: May 2010 update

Cuisset T, Valgimigli M, Mudra H, Mueller O, Wijns W, Huber K

May 25, 2010

Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions

Cuisset T, Mudra H, Mueller O, Vogt P, Angelillo-Scherrer A, Huber K

August 20, 2008

Suessenbacher A, Doerler J, Alber H, Aichinger J, Altenberger J, Benzer W, Christ G, Globits S, Huber K, Karnik R, Norman G, Siostrzonek P, Zenker G, Pachinger O, Weidinger F

August 20, 2008

Latest news

NEW ISSUE

Robotics, AI and Imaging State of The Art; Bleeding Risk and Mortality in CAD; Treating Refractory Angina by Coronary Sinus Narrowing; and more

September 20, 2021

STATE OF THE ART

Robotics, imaging, and artificial intelligence in the catheterisation laboratory

Rafael Beyar et al.

September 20, 2021

AHEAD OF PRINT

ViV TAVI vs repeat SAVR

Monil Majmundar et al.

September 15, 2021

AHEAD OF PRINT

Thrombectomy for ischaemic stroke

Christopher A. Rajkumar et al.

September 10, 2021

EDITORIAL

Walking the tightrope between ischaemia and bleeding

Michelle L. O’Donoghue et al.

September 20, 2021

EDITORIAL

Microvascular dysfunction endotypes and outcomes

Christos V. Bourantas et al.

September 20, 2021

EDITORIAL

Coronary sinus reducer therapy for refractory angina: is it ready for prime time?